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Abstract
Background:  The relationship between diabetes mellitus (DM) and chronic musculoskeletal
complaints (MSCs) is unclear. The aim of this study was to investigate the association between DM,
non-fasting glucose and chronic MSCs defined as pain and/or stiffness ≥ 3 months during the past
year in the general adult population.
Methods: The results were based on cross-sectional data from 64,785 men and women (aged ≥
20 years) who participated in the Nord-Trøndelag Health Survey, which included 1,940 individuals
with known DM. Associations were assessed using multiple logistic regression, estimating
prevalence odds ratio (OR) with 95% confidence intervals (CIs).
Results:  High non-fasting glucose was associated with a lower prevalence of chronic MSCs
compared to a low glucose level. DM was associated with higher prevalence of chronic MSCs, in
particular chronic widespread MSCs. In the multivariate analysis, adjusting for glucose level, BMI,
age, gender and physical activity, chronic widespread MSCs was 1.6 times more likely (OR = 1.6,
95% CI 1.2–2.2) among individuals < 60 years of age with DM than among those without DM. The
association between chronic widespread MSCs and DM was most evident among the group of
individuals aged < 60 years with either type 2 DM or unclassified DM (OR = 1.8, 95% CI 1.3–2.5).
Conclusion: In this cross-sectional study a high non-fasting glucose was associated with lower
prevalence of chronic MSCs. Among individuals with known DM chronic widespread MSCs were
more likely.
Background
Musculoskeletal complaints (MSCs) are among the major
health problems worldwide and the most frequent cause
of long-term sickness leave in Norway [1,2]. Increased
mortality has been reported among individuals with
chronic widespread MSCs [3], which further emphasizes
that this group of patients may constitute an important
public health problem.
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In Nord-Trøndelag County in Norway 45% of the adult
population reported chronic MSCs during the last year
[4]. The prevalence of known diabetes mellitus (DM) was
3% [5]. Despite that both disorders are relatively com-
mon, few studies have focused on the relationship
between chronic MSCs and diabetes mellitus (DM). DM
has been associated with increased fracture risk [6] and
rotator cuff tendinitis [7]. Some studies have reported
reduced pain thresholds in individuals with hyperglyc-
emia [8,9], but the relationship between DM and chronic
MSCs remains unclear.
To clarify the potential association between DM and
chronic MSCs a cross-sectional study is a time effective
first-step which also may provide clues to the pathophys-
iology of chronic MSCs. The main purpose of this large
population-based cross-sectional study was to evaluate
the association between DM, non-fasting glucose and
chronic MSCs.
Methods
Between 1995 and 1997, all inhabitants aged 20 years and
above were invited to participate in the Nord-Trøndelag
Health Survey (the HUNT study). Details of this compre-
hensive health study are described elsewhere [10]. In
short, two questionnaires including more than 200
health-related questions were administered to the partici-
pants. The first questionnaire (Q1) was sent along with
the invitation, and delivered when attending the health
examination during which non-fasting blood samples
were drawn. All participants received a second question-
naire (Q2) which was returned by postal mail. Out of the
92,936 invited individuals, 65,081 (70.0%) answered the
first question about DM, whereas 64,785 (69.7%)
responded to the first question about MSCs.
Musculoskeletal complaints
Both Q1 and Q2 included questions about musculoskele-
tal symptoms adopted from the Standardized Nordic
Questionnaire, which has previously been evaluated and
found to give reliable estimates for low back and upper
limb and neck discomfort, in particular for symptoms
during the past year [11-13]. In Q1 participants were
asked whether they had suffered pain or stiffness in mus-
cles and joints lasting for at least 3 months during the last
year, whereas in Q2, they were asked to indicate the
number of days during the last month of such complaints.
In both questionnaires, those participants who responded
"yes" were then asked to tick off one or several of the fol-
lowing nine areas of the body; neck, shoulders, elbows,
wrist/hands, upper back, low back, hips, knees, and/or
ankles/feet.
In the present study, individuals with chronic MSCs (pain
and/or stiffness ≥ 3 months during the past year) were
subdivided into chronic widespread MSCs and chronic
non-widespread MSCs. "Chronic widespread MSCs" were
defined as pain and/or stiffness ≥ 3 month during the past
year and ≥ 15 days with symptoms during the last month
from all of the following regions: axial skeletal pain (pain
in the neck, chest/abdomen, upper back, or lower back),
pain above the waist (neck, shoulders, elbows, wrist/
hands, chest/abdomen, or upper back) and below the
waist (lower back, hips, knees, or ankles/feet). Individuals
with chronic MSCs not fulfilling the criteria for chronic
widespread MSCs were defined as having chronic non-
widespread MSCs (mutually exclusive).
Diabetes mellitus
Non-fasting glucose was drawn from more than 99% of
the participants who attended the clinical examination.
Fasting glucose, glycosylated hemoglobin (HbA1c), C-
peptide and anti-glutamic acid decarboxylase (anti-GAD)
was drawn from 74% of the participants with a positive
answer to the question "Do you have or have you ever had
diabetes?" in Q1 (known DM). Known DM was reported
in a total of 1,940 (3%) out of the 64,785 participants
who responded to the first question about MSCs. A total
of 216 persons with no previous known DM had non-fast-
ing glucose ≥ 11.1. Although a considerable proportion of
these probably had previously undiscovered DM, these
were included as a separate group in our analyses.
Patients starting insulin treatment within 6 months of
diagnosis were classified as having type 1 DM (classic type
1), if, in addition, they were anti-GAD positive (≥ 0.08) or
had C-peptide levels < 150 pmol/l (n = 122). Type 2 dia-
betic subjects were anti-GAD negative (< 0.08) and had
not received insulin treatment within one year of diagno-
sis (n = 1120). LADA was defined by anti-GAD positivity
and no insulin treatment within 12 months after diagno-
sis (n = 127). For gestational diabetes mellitus (GMD) the
criteria were anti-GAD negative and no insulin treatment,
and/or other information about diabetes during preg-
nancy (n = 12). The criteria for MODY were anti-GAD neg-
ative and debut < 25 years and diabetes in relatives and no
insulin treatment started within 12 months after debut (n
= 8). Only 20 persons fulfilled the criteria for MODY or
GDM, and these were therefore merged together with the
unclassified group, consisting of patients with incomplete
information on insulin treatment and results of C-peptide
and anti-GAD.
Statistical analysis
Differences between continuous variables were tested
with analyses of variance (one-way ANOVA) and between
proportions by chi-squared test. In the multivariate anal-
yses, using logistic regression, we estimated the prevalence
odds ratio (OR) with 95% confidence interval (CI) for the
association between chronic MSCs and DM. We adjustedBMC Musculoskeletal Disorders 2008, 9:160 http://www.biomedcentral.com/1471-2474/9/160
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for age, body mass index (BMI), gender and physical activ-
ity as confounders. Other potential confounding factors
like education, occupation, smoking, previous myocardial
infarction, alcohol consumption, and mean systolic
blood pressure were also evaluated, but were excluded
from the final analyses because they changed the OR by
less than 5%. Serum glucose, HbA1c, and duration of DM
were categorized into quartiles based on individual val-
ues, but in separate analyses also treated as a continuous
variable. When appropriate, serum glucose was also
treated as a single ordinal variable (categories 1 to 4 based
on quartiles) and was incorporated in a two sided test for
trend to evaluate the probability of a linear relationship
between glucose categories and prevalence of MSCs. We
also investigated potential interaction between age and
diabetes status by including the product of the two varia-
bles into the logistic regression analyses. The interaction
coefficient was tested using Wald χ2 statistics. Data analy-
ses were performed with the Statistical Package for the
Social Sciences, version 15.0 (SPSS, Chicago, Illinois,
USA)
The study was approved by the Regional Committee for
Ethics in Medical Research, and the HUNT Study is also
approved by the Norwegian Data Inspectorate.
Results
Among the 64,785 participants, 30,157 (46.5%) reported
chronic MSCs, whereof 3,240 (5.0%) had chronic wide-
spread MSCs, and the remaining 26,917 (41.5%) chronic
non-widespread MSCs. The prevalence of chronic MSCs
increased with age with a peak in the age group 60–64
years (59.7%), and were higher for women than men in
all age groups (overall 50.1% versus 42.6%, p < 0.001).
The prevalence of chronic MSCs also increased with BMI
with a peak among obese with BMI ≥ 30 kg/m2 (54.6%),
and were higher among the physically inactive than active
individuals (55.4% versus 44.9, p < 0.001).
Educational level, level of physical activity, and propor-
tion of smokers were lower among individuals with DM
compared to those without DM, whereas, age, BMI, mean
systolic BP, and prevalence of alcohol abstainers and
myocardial infarction were significantly higher (p <
0.001) Table 1). The proportion of women did not differ
significantly between the groups with or without DM (p =
0.20). Among individuals with DM, those with type 1 DM
was youngest and most likely to be men (Table 1).
In the multivariate analyses, adjusting for age, BMI, gen-
der and level of physical activity as confounding factors,
prevalence of chronic MSCs was higher among patients
with DM than among individuals without (OR = 1.2, 95%
CI 1.1–1.3, Table 2). This association was most evident
among individuals with chronic widespread MSCs (OR =
1.3, 95% CI 1.1–1.6). The difference in unadjusted preva-
lence of chronic widespread MSCs between individuals
with or without DM was most prominent in those below
60 years of age (Fig. 1). Although no significant interac-
tion was found between age and diabetes status in the
multivariate analyses (p = 0.16), chronic widespread
MSCs was 1.5 times more likely (OR = 1.5, 95% CI 1.1–
2.1) among subjects with DM than among those without
in a separate analysis for individuals < 60 years. Among
those 60 years and older, the corresponding OR was 1.1
(0.8–1.5).
Among the group of 216 individuals with non-fasting glu-
cose ≥ 11.1 (but not known DM), chronic MSCs was less
likely (OR = 0.7, 95% CI 0.5–0.9) than among those with
no DM (Table 2). Furthermore, there was a linear trend (p
< 0.001) of decreasing prevalence of chronic MSCs with
Table 1: Background data on persons without and with known diabetes mellitus (DM) (type 1, type 2, type 2, LADA, and other types/
unclassified)
Variables No DM All DM types Classical
Type 1 DM
Type 2 DM LADA Other types/unclassified 
DM
Not DM, but glucose ≥ 
11.1
n 62,626 1940 122 1120 127 571 216
Gender, female (%) 53.2 51.7 41.0 50.5 46.5 57.4 37.5
Mean age 48.4 64.4 47.5 67.1 67.4 63.1 61.6
Years of education ≥ 13 
(%)
19.3 9.1 19.7 6.5 11.0 10.3 12.0
Mean BMI 26.3 29.0 26.1 29.6 28.5 28.6 29.5
Current smoking (%) 28.9 17.5 24.6 15.4 9.4 21.9 26.9
High physical activity* (%) 16.1 7.8 13.9 7.2 11.0 6.8 4.6
Alcohol abstainers (%) 12.2 30.8 13.7 32.0 36.1 31.0 17.2
Previous myocardial 
infarction
3.0 12.7 5.7 13.5 12.0 12.9 5.6
Mean systolic blood 
pressure
137 154 140 156 154 153 156
* High physical activity level = ≥ 3 hours/week with hard physical activityBMC Musculoskeletal Disorders 2008, 9:160 http://www.biomedcentral.com/1471-2474/9/160
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increasing non-fasting glucose categories, also evident
when glucose was treated as a continuous variable (Table
2). The prevalence OR of chronic widespread MSCs was
0.8 (95% CI 0.7–0.9) for individuals with glucose ≥ 5.9
mmol/l compared to those with glucose ≤ 4.7 mmol/l
(Table 2). Thus, when adjusting for non-fasting serum
glucose, chronic widespread MSCs was 1.6 times more
likely (OR = 1.6, 95% CI 1.2–2.2) among subjects < 60
years of age with DM than among those without.
Chronic widespread MSCs were more likely among indi-
viduals with type 2 DM (OR = 1.3, 95% CI 1.0–1.7) and
unclassified DM (OR = 1.6, 95% CI 1.1–2.3) than among
those without DM (Table 2). When adjusting for non-fast-
ing glucose, the corresponding ORs increased to 1.4 (95%
CI 1.1–1.8) and 1.7 (95% CI 1.2–2.5) respectively.
Among women, the strongest association was found with
unclassified DM (OR = 2.1, 95% CI 1.3–3.3), whereas for
type 2 DM among men (OR = 1.5, 95% CI 1.0–2.2). When
merging individuals with type 2 DM and unclassified DM,
chronic widespread MSCs were 1.5 times more likely (OR
= 1.5, 95% CI 1.2–1.9) for this combined group com-
pared to those without DM. The corresponding OR for
those < 60 years was 1.8 (1.3–2.5). No significant associ-
ation was found between chronic MSCs and type 1 DM or
latent autoimmune diabetes of the adult (LADA) (Table
2).
Among the group of 1940 individuals with DM, no clear
association was found between chronic MSCs and neither
non-fasting serum glucose, HbA1c, nor duration of DM
when treated as a single ordinal variable (Table 3). How-
ever, when HbA1c was treated as a continuous variable,
there was a linear trend (p < 0.036, β = -,055) of decreas-
ing prevalence of chronic non-widespread MSCs with
increasing HbA1c.
Discussion and conclusion
In this large-scale population-based cross-sectional study
a high non-fasting glucose was associated with a lower
prevalence of chronic MSCs, whereas individuals with
DM were more likely to report chronic widespread MSCs
than those without DM.
The strength of this study was the large and unselected
population. To the best of our knowledge, this is the first
large-scale population-based study evaluating the influ-
ence of chronic MSCs on individuals with DM whose clas-
sification is based on results of blood samples with anti-
GAD and C-peptide in addition to questionnaire-based
data. Although the participation rate of 70% was high,
one may question to what degree the results can be gener-
alized. Because questions about musculoskeletal pain
were only a few out of more than 200 health-related ques-
tions, there is probably no selection bias regarding
Prevalence (%) of chronic widespread MSCs by age group Figure 1
Prevalence (%) of chronic widespread MSCs by age group. * p < 0.05.
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Table 2: Prevalence OR# of musculoskeletal complaints (MSCs) related to DM and non-fasting glucose levels
Variables Total Chronic MSCs Chronic widespread MSCs MSCs Chronic non-widespread MSCs
64,785 % OR (CI) % OR (CI) % OR (CI)
DM
No 62,629 46.2 1.0 (reference) 5.0 1.0 (reference) 41.3 1.0 (reference)
Yes 1,940 56.9 1.2 (1.1–1.3) 5.9 1.3 (1.1–1.6) 51.0 1.1 (1.0–1.3)
No, but glucose ≥ 11.1 216 45.4 0.7 (0.5–0.9) 5.1 0.8 (0.4–1.5) 40.3 0.7 (0.5–0.9)
DM
No 62,629 42.2 1.0 (reference) 5.0 1.0 (reference) 41.3 1.0 (reference)
Type 1 122 45.9 1.0 (0.7–1.5) 3.3 0.7 (0.2–1.9) 42.6 1.1 (0.7–1.6)
Type 2 1,120 57.7 1.1 (1.0–1.3) 6.1 1.3 (1.0–1.7) 51.6 1.1 (1.0–1.3)
LADA 127 56.7 1.1 (0.8–1.6) 5.5 1.2 (0.5–2.6) 51.2 1.2 (0.8–1.7)
Unclassified 571 57.8 1.2 (1.0–1.5) 6.3 1.6 (1.1–2.3) 51.5 1.2 (1.0–1.4)
No, but glucose ≥ 11.1 216 45.4 0.7 (0.5–0.9) 5.1 0.8 (0.4–1.5) 40.3 0.7 (0.5–0.9)
Serum glucose
≤ 4.7 mmol/l 16,198 43.2 1.0 (reference) 4.8 1.0 (reference) 38.3 1.0 (reference)
4.8–5.2 mmol/l 19,151 46.7 1.0 (0.9–1.0) 5.2 1.0 (0.9–1.1) 41.4 1.0 (0.9–1.0)
5.3–5.8 mmol/l 14,737 47.9 0.9 (0.9–1.0) 5.1 0.9 (0.8–1.0) 42.8 0.9 (0.9–1.0)
≥ 5.9 mmol/l 14,316 49.1 0.9 (0.8–0.9) 5.0 0.8 (0.7–0.9) 44.2 0.9 (0.8–0.9)
Missing 383 36.6 0.6 (0.5–0.8) 0.8 0.1 (0.0–0.4) 35.8 0.6 (0.5–0.8)
P-trend value$ < 0.001 < 0.001 < 0.001
P trend value$ (β) < 0.001 (-,022) 0.045 (-,026) < 0.001 (-,021)
# Adjusted for age, gender, body mass index, and level of physical activity
$ Serum glucose treated as a single ordinal variable (categories 1 to 4 based on quartiles)
§ Serum glucose treated as a continuous variable (β value given in brackets)
Table 3: Prevalence OR# of musculoskeletal complaints (MSCs) related to fasting serum glucose, HbA1c and duration of the disease in 
patients with DM
Variables Total Chronic MSCs Chronic widespread MSCs Chronic non-widespread MSCs
1940 % OR (CI) % OR (CI) % OR (CI)
Serum glucose
≤6.3 mmol/l 482 59.3 1.0 (reference) 6.4 1.0 (reference) 52.9 1.0 (reference)
6.4–8.7 mmol/l 487 55.2 0.8 (0.6–1.1) 5.1 0.7 (0.4–1.2) 50.1 0.8 (0.6–1.1)
8.8–12.1 mmol/l 472 54.9 0.8 (0.6–1.1) 6.1 0.8 (0.5–1.4) 48.7 0.8 (0.6–1.1)
≥12.2 mmol/l 469 57.4 1.0 (0.7–1.3) 6.4 1.0 (0.6–1.8) 51.0 1.0 (0.7–1.3)
Missing 30 70.0 1.2 (0.5–3.0) 0.0 - 70.0 1.5 (0.6–3.6)
HbA1c
≤6.8 mmol/l 509 57.2 1.0 (reference) 6.7 1.0 (reference) 50.5 1.0 (reference)
6.9–7.8 mmol/l 422 59.2 1.1 (0.9–1.5) 5.0 0.8 (0.4–1.5) 54.3 1.2 (0.9–1.5)
7.9–9.2 mmol/l 481 55.7 1.0 (0.7–1.2) 5.2 0.8 (0.5–1.4) 50.5 1.0 (0.8–1.3)
≥9.3 mmol/l 426 53.8 0.9 (0.7–1.2) 7.0 1.0 (0.6–1.7) 46.7 0.9 (0.7–1.2)
Missing 102 64.7 1.4 (0.9–2.1) 4.9 0.8 (0.3–2.4) 59.8 1.4 (0.9–2.3)
Duration of DM
≤2 years 502 56.2 1.0 (reference) 6.4 1.0 (reference) 49.8 1.0 (reference)
3–6 years 360 56.4 1.0 (0.8–1.4) 4.7 0.8 (0.4–1.4) 51.7 1.1 (0.8–1.4)
7–13 years 403 57.1 1.1 (0.8–1.4) 6.0 1.1 (0.6–2.1) 51.1 1.1 (0.8–1.5)
≥14 years 406 59.1 1.2 (0.9–1.6) 6.9 1.6 (0.9–2.8) 52.2 1.2 (0.9–1.6)
Missing 269 55.4 1.0 (0.7–1.3) 5.2 1.0 (0.5–2.1) 50.2 1.0 (0.7–1.3)
# Adjusted for age, gender, body mass index, and level of physical activity
$ Serum glucose treated as a single ordinal variable (categories 1 to 4 based on quartiles)
§Serum glucose treated as a continuous variable (β value given in brackets)BMC Musculoskeletal Disorders 2008, 9:160 http://www.biomedcentral.com/1471-2474/9/160
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chronic MSCs. However, the possibility of a recruitment
bias regarding DM should not be ignored. Non-respond-
ers were more frequent among young persons and among
very old [10]. Particular selection by health status was
more likely among the elderly [14]. The non-response
problems related to the HUNT study have been thor-
oughly discussed elsewhere [14].
The participants were not asked to distinguish between
pain in the left and right side of the body, and therefore
we could not use the American College of Rheumatology
(ACR) definition of chronic widespread pain. The group
of individuals with chronic widespread MSCs was proba-
bly heterogeneous, but it may be of some relevance that a
self-reported diagnosis of fibromyalgia was more than 5
times more common among individuals with chronic
widespread MSCs than in those without. In the present
study DM was associated with an increased prevalence of
chronic widespread MSCs. A high prevalence of fibromy-
algia has been reported among 100 patients with DM,
both in type 1 and type 2, and a positive correlation
between higher levels of HbA1c and more tender points
[15]. Similarly, fibromyalgia was more likely among
women with type 2 DM compared to controls [16], and
the majority of a group of Italian patients with DM
reported chronic musculoskeletal pain [17]. In the present
study we found the strongest association between chronic
widespread MSCs and the combined group of individuals
with type 2 DM or unclassified DM. The positive relation-
ship between type 2 DM and chronic widespread MSCs
found in the present study raises the question whether
type 2 DM may in some ways worsen chronic widespread
MSCs, or vice versa. The causality issue cannot be properly
addressed in a cross-sectional study. Age, overweight, and
physical inactivity are strong risk factors for type DM [18],
but we adjusted for all these factors in the analysis, and
potential confounding was also evaluated for other life-
style factors such as smoking and alcohol use. However,
one can not rule out the possibility that there may be
other unmeasured life-style factors or other factors incom-
pletely registered that could influence our findings. For
example, among those with known DM, anxiety and other
psychological factors may influence their response to the
questions about MSCs. One may also speculate that
attempts to keep the glucose level low may influence the
occurrence of chronic MSCs. DM affects vascular reactivity
[19,20], and induces diabetic neuropathy [21], but
because no association was found between chronic MSCs
and type 1 DM or LADA, other causes than vascular
changes may probably explain our main findings.
To the best of our knowledge, this is the first study evalu-
ating the influence of non-fasting glucose on chronic
MSCs in the general population. A subgroup of 216 indi-
viduals had non-fasting glucose ≥ 11.1, but they were not
aware of DM at the time of the blood sampling. Therefore,
anxiety for DM probably did not influence their response
to the questions about MSCs. We found that hyperglyc-
emia was associated with lower prevalence of chronic
MSCs. Thus, our findings did not indicate that hyperglyc-
emia per se increased the risk of chronic pain, at least in a
short time perspective. Previously, several studies have
reported reduced pain thresholds in hyperglycemia, but
these studies have mainly been restricted to patients with
known DM or diabetic animals [9,22-24]. In the present
study no consistent association was found between non-
fasting glucose, HbA1c, and prevalence of chronic MSCs
among those with known DM. Thus, our results did not
indicate that poor control of DM increases the prevalence
of chronic MSCs as compared to good control defined as
low HbA1c or low non-fasting glucose level.
In the present study high non-fasting glucose was associ-
ated with a lower prevalence of chronic MSCs, which may
provide clues to the pathophysiology of chronic MSCs.
High glucose levels or poor control of DM can of course
not be recommended in a public health perspective.
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